Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Teen Symposium: Engaging Adolescents and Young Adults With Sickle Cell Disease in Clinical Care and Research
source: Clinical Practice in Pediatric Psychology
year: 2020
authors: Crosby, Lori E. Strong, Heather Johnson, Alisha Mitchell, Monica J
summary/abstract:Objective:
In the United States, sickle cell disease (SCD) is the most prevalent genetic disorder affecting African American and Hispanic youth. Disparities in care have been reported for this population with adolescents and young adults (AYA) with SCD at increased risk for poor health outcomes. It is essential that AYA with SCD receive high-quality care and have access to disease-modifying therapies, yet engaging them in their care and clinical research studies to discover new treatments remains a challenge.
Method:
Our team developed an innovative approach to engage AYA with SCD in clinical care and research: the SCD Teen Symposium, which uses motivational interviewing strategies to educate AYA with SCD, their family members, and friends while providing concurrent opportunities for research participation.
Results:
Over a 6-year period, 81 AYA with SCD (47% male; Mage = 14.58, SD = 2.9) and 162 family and friends (48% male; Mage = 13.37, SD = 2.1) participated. Participants rated the symposium as acceptable (Mrating = 1.74, SD = 0.85) on a scale from 1 (excellent) to 5 (poor), and 72% reported they would recommend it to others. Research was rated as very important (Mrating = 1.21, SD = 0.46) by 81% of attendees on a scale from 1 (very important) to 4 (not important), and 82% reported increased trust in research. AYA suggested improvements including separate programming for younger and older teens.
Conclusions:
Results support the feasibility of the Teen Symposium as a model for increasing trust and potentially increasing participation in research. Future studies will determine whether it can be disseminated by other SCD clinics.
DOI: 10.1037/cpp0000323
read more
Related Content
-
Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
-
Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased ...Treatment of vaso-occlusive crises (VOC)...
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseBackground: Deoxygenated sickle hemog...
-
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Depende...First patient with severe sickle cell di...
-
New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial ShowsA new pre-transplant conditioning regime...
-
Review Board Finds Global Blood’s Sickle Cell Disease Therapy Voxelotor Is SafeAn independent review board has found Gl...
-
Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.